Life-threatening anaphylactic shock following cisplatin application: Case report and recent therapy concepts;Lebensbedrohliche Anaphylaxie nach wiederholter Cisplatin-Gabe: Fallbericht und neue Therapiekonzepte

Zentralblatt fur Gynakologie

Volumn 118, Issue 12, 1996, Pages 684-688

  Berg, K ^a   Grundmann, U ^a   Villena Heinsen, C ^a   Wilhelm, W ^a   Mertzlufft, F ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

cisplatin anaphylaxis; interdisciplinary therapy; ovarian carcinoma; oxygen storage capacity

Indexed keywords

CAFEDRINE PLUS THEODRENALINE; CISPLATIN; CORTISONE; METHYLPREDNISOLONE; VASOCONSTRICTOR AGENT;

ADULT; ANAPHYLACTIC SHOCK; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; FEMALE; HUMAN; OVARY CARCINOMA;

ANAPHYLAXIS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PATIENT CARE TEAM; RECURRENCE;

EID: 0030452544     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ahnefeld FW, Barth J, Dick W et al: Akuttherapie anaphylaktoider Reaktionen. Anaesthesist 43 (1994) 211-222
2. Bonomi P, Blessing JA, Stehman B, DiSaia PJ, Walton L, Major FJ: Randomized Trial of Three Cisplatin Dose Schedules in Squamous-Cell Carzinoma of the Cervix: A Gynecologic Oncology Group Study. J Clin Oncol 3 (1985) 1079-1085
3. Dottino PR, Plaxe SC, Cohen CJ: A Phase II Trial of Adjuvant Cisplatin and Doxorubicin in Stage I Epithelial Ovarian Cancer. Gynecologic Oncology 43 (1991) 203-205
4. Goldberg A, Altaras MM, Mekori YA, Beyth Y, Confino-Cohen R: Diagnosis and value of pretreatment in prevention of recurrent allergic reactions. Ann Allergy 73 (1994) 271-272
5. Goodnight JE, Moseley HS, Eilber FR,Sarna G, Morton DL: cis-Dichloroammineplatinum (II) alone and compined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Pep 63 (1979) 2005-2007
6. Gregg R W, Molepo JM, Monpetit VJA, Mikael NZ, Redmond D. Gadia M. Stewart DJ: Cisplatin Neurotoxicity: The Relatioship Between Dosage, Time, and Platinium Concentration in Neurologic Tissues, and Morphologic Evidence of Toxicity. J Clin Oncol 10 (1992) 795-803
7. Khan A, Hill J, Grater W, Loeb E, MacLellan A, Hill N: Atopic hypersensitivity to cis-dichlorodiammineplatinum (II) and other platinum complexes. Cancer Res 35 (1975) 2766-2770
8. 2-Speicherung mit dem NasOral-System. Anästhesiol Intensivmed Notfallmed Schmerzther 29 (1994) 235-237
9. Ozols RF, Ostchega Y, Myers CE, Young RC: High-Dose Cisplatin in Hypertonic Saline in Refractory Ovarian Cancer. J Clin Oncol 3 (1985) 1246-1250
10. Ozols RF, Young RC: Chemotherapy of ovarion cancer. Semin Oncol 11 (1984) 251-263
11. Reichman B, Markman M, Hakes T, Budnick A, Rubin S, Jones W, Almadrones L, Lewis JL, Hoskins W: Phase II Trial of High-Dose Cisplatin with Sodium Thiosulfate Nephroprotection in Patients with Advanced Carcinoma of the Uterine Cervix Previously Untrated with Chemotherapy. Gynecol Oncol 43 (1991) 159-163
12. Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM, Reed E, Young RF: Dose-Intensive Induction Therapy With Cyclophosphamide, Cisplatin, and Consolidative Abdominal Radiation in Advanced-Stage Epithelial Ovarian Cancer. J Clin Oncol 10 (1992) 727-734
13. Saunders MP, Denton CP, O'Brien ME, Blake P, Gore M. Wiltshaw E: Hyper-sensitivity reactions to cisplatin and carboplatin: a report on six cases. Ann Oncol 3 (1992) 574-576
14. Weisenfeld M, Reinders E, Corder M, Yoo T, Dietz B, Lovett J: Successful retreatment with cis-dichlorodiammineplatin (II) after apparent allergic reactions. Cancer Treat Rep 63 (1979) 219-221
15. Weiss RB, Bruno S: Hypersensitivity to cancer chemotherapeutic agents. Ann Int Med 94 (1981) 66-72
16. Zweizig S, Roman LD, Muderspach LI: Death from Anaphylaxis to Cisplatin: A Case Report. Gynecol Oncol 53 (1994) 121-122